|
| Brand Name: | LIBANG |
| MOQ: | 30,000 boxes |
| Price: | to be negotiated |
| Payment Terms: | T/T, L/C |
| Supply Ability: | 50,000,000 capsules |
PHARMACOLOGICAL ACTIONS
Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly.
Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide
The micronised formulation of fenofibrate(Φ < 50μm) was developed to enhance fenofibrate absorption and allow for once-daily administration. The micronised fenofibrate capsule formulation is 30% more bioavailable than a non-micronized preparation. It can reduces triglycerides by 40% to 50%, increases HDL-C by 10% to 20%, reduces LDL-C by 20% to 25%, reduces total cholesterol by 17% to 22% and reduces cardiac infarcation by 34%.
INDICATIONS
For use as adjunctive therapy to diet for the reduction of elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb) and also for the treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia).
